Loading
NASDAQHealthcareBiotechnology
Latest quote
$37.22
+$2.61 · +7.54%
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Latest quote
$37.22
+$2.61 · +7.54%
Regular session · ET · Market data may be delayed.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
34
Moderate Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 16.74M USD | 51.17M USD | 7.85M USD | 1.35M USD |
| Selling, general, and administrative | 13.66M USD | 13.66M USD | 3.53M USD | 1.46M USD |
| Operating expenses | 30.4M USD | 64.83M USD | 11.38M USD | 2.81M USD |
| Interest income | 3.92M USD | 1.72M USD | 811K USD | 73K USD |
| Interest expense | — | — | 4.83M USD | 2.15M USD |
| Depreciation and amortization | 321K USD | 91K USD | 4K USD | 2K USD |
| Operating income | −30.4M USD | −64.83M USD | −11.38M USD | −2.81M USD |
| Net income | −25.21M USD | −63.1M USD | −6.28M USD | −14.35M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI32.33M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM20.47M0.03%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF13.37M0.01%95.4B USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO6.07M0.03%18B USD0.06%$112.66+0.50%
State Street SPDR S&P Pharmaceuticals ETFXPH5.87M1.27%461.57M USD0.35%$64.65+1.60%
Schwab U.S. Small-Cap ETFSCHA4.65M0.02%21.82B USD0.03%$32.79+0.40%
iShares Russell 2000 Growth ETFIWO3.44M0.02%13.92B USD0.24%$356.78+0.94%
iShares U.S. Pharmaceuticals ETFIHE3.03M0.20%1.55B USD0.37%$100.09+1.24%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOiShares U.S. Pharmaceuticals ETFIHEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
